newsfilter
← Latest News
Business Wire·

Cosette Pharma’s RYANODEX® (dantrolene sodium) for Injectable Suspension, Fully Stocked and Available

  • Cosette Pharmaceuticals maintains full availability of RYANODEX for injectable suspension in U.S. & international markets following its June 2026 acquisition from Eagle Pharmaceuticals.
  • The company successfully completed a supply chain transition & leverages its manufacturing & distribution capabilities to ensure a dependable supply of the drug.
  • CEO Apurva Saraf stated the acquisition reflects Cosette's commitment to expanding access to important medicines while ensuring supporting infrastructure is in place.
  • VP Brad Leonard emphasized that ensuring hospitals & healthcare providers have dependable access to RYANODEX allows them to focus on delivering timely patient care.
  • Cosette Pharmaceuticals is a U.S.-based specialty company headquartered in Bridgewater, New Jersey, with 350+ team members & is backed by Avista Healthcare Partners & Hamilton Lane.